Watts Gwilliam & Co. LLC Has $1.11 Million Position in Johnson & Johnson $JNJ

Watts Gwilliam & Co. LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,720 shares of the company’s stock after buying an additional 82 shares during the period. Watts Gwilliam & Co. LLC’s holdings in Johnson & Johnson were worth $1,114,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Highline Wealth Partners LLC boosted its position in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new position in Johnson & Johnson during the first quarter valued at approximately $47,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson during the first quarter valued at approximately $49,000. Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the first quarter valued at approximately $52,000. Finally, Capital A Wealth Management LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $50,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on JNJ. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Leerink Partners cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Bank of America raised their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Thursday, July 17th. Finally, Barclays raised their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $174.50.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $176.76 on Monday. The stock’s fifty day moving average price is $161.28 and its two-hundred day moving average price is $158.43. Johnson & Johnson has a one year low of $140.68 and a one year high of $177.27. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market cap of $425.70 billion, a PE ratio of 18.90, a price-to-earnings-growth ratio of 2.25 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the company earned $2.82 EPS. The company’s revenue was up 5.8% on a year-over-year basis. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.